TNF-α and IL-6 are proinflammatory factors with the synergistic effect, which can promote the progress of liver fibrosis and inflammation in patients, while the incidence of adverse reactions in patients is the key index to evaluate the effect of drug therapy [20]. The gene discussed is TNF; the disease is Hepatic fibrosis.